Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Eli Lilly (NYSE: LLY) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and rising patient volumes can generate durable earnings sufficient to overcome pricing
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
